Who makes CENATONE tablet?

CENATONE tablet is developed by PMG Pharm Co., Ltd.

What development phase is CENATONE tablet in?

CENATONE tablet is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CENATONE tablet

PMG Pharm Co., Ltd · FDA-approved active Small molecule Quality 0/100

CENATONE, a tablet marketed by PMG Pharm Co., Ltd, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established patient base and brand recognition. The primary risk to CENATONE is the potential increase in competition following the 2028 patent expiry, which could erode market share and revenue.

At a glance

Generic name	CENATONE tablet
Also known as	Nabumetone 500mg
Sponsor	PMG Pharm Co., Ltd
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CENATONE tablet CI brief — competitive landscape report
CENATONE tablet updates RSS · CI watch RSS
PMG Pharm Co., Ltd portfolio CI